Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. - Wikidata - awgldk - TriplyDB

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

http://www.wikidata.org/entity/Q33370331

about

Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review Update on clinical research and state of the art management of patients with advanced sarcomas and GIST Osteosarcoma in Korean children and adolescents Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Trabectedin and its potential in the treatment of soft tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review Emerging therapies for adult soft tissue sarcoma.Recent advances in understanding and managing leiomyosarcomas The off-label use of targeted therapies in sarcomas: the OUTC'S program Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas.Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma.A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Current concepts in multimodality therapy for retroperitoneal sarcoma.Adult human sarcomas. II. Medical oncology.Emerging drugs for the treatment of soft tissue sarcomas.Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.Pharmacotherapy of sarcoma.Phase III Soft Tissue Sarcoma Trials: Success or Failure?Targeted therapy for soft tissue sarcomas in adolescents and young adults.Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.

P2860

Q26822530-E5901AFD-B902-4270-8CDF-13102D10FCF3 Q28073290-9E6E555C-F676-4049-914A-577708CC355B Q28083794-A089CA4E-BCFA-4A06-A186-DC3A4E987DA5 Q28087771-95290671-C7A5-41F8-BBA3-88053418E3D5 Q33379886-E01F6698-C50A-412D-8156-219BC196082C Q33380903-275152B6-16F5-48C8-AFAF-7723A7D58B03 Q33384836-B8BF9BF8-F43D-4FA6-BD75-8263F290C805 Q33400959-D73CAA7C-0496-4298-8D90-D1AD98AADD71 Q33427160-5E42A865-3377-4A51-A525-121E259324DF Q33439510-02DC486F-364F-4926-B152-ADD24980D527 Q33523297-8188373B-4DB6-4950-9EBD-A9D1BA02F5BA Q33657779-DFF61DB5-F304-4E18-99FC-2FE2BA94A3E0 Q33872963-DAB255B1-7265-476C-8828-B64FE966C1E1 Q34659806-933965D9-DC68-4ABE-BFB0-9907F146418F Q34670825-7A78C229-0627-4E55-B3B7-59B9ABB490D1 Q34897996-4EAF2597-82BD-4995-A3E5-55A8EF657EEF Q35060432-67D55933-2E95-43B1-8E97-F9071CC14D2F Q35220458-3ACCE5BC-EA33-4172-8973-17E4560B7927 Q35602294-A2A76376-139F-4D80-A279-F2F659AE03A4 Q35616803-16416086-952C-4C5C-A2C9-E38CDDBD44B1 Q35758538-66044EE7-71A7-4B5D-8867-C0BA16C8ABAB Q35877763-F55CC171-AE06-41A0-BF2C-683F71E2772A Q36144210-C4FEF244-01A7-448A-B0B0-4CC94FC1EC10 Q36251435-67E4F6ED-DF3C-4D9C-98FC-59B702CC4594 Q36444369-343930F6-C735-4117-8384-CD5862E9F691 Q36731422-6EADFCF4-F36B-44AA-972B-B9027266BFCF Q36731430-0AAD5EFE-56AD-42CE-A064-A82717532FB4 Q36758596-6163BA5F-1E17-4F72-8E0B-63525A51B3D2 Q36895793-4F1C2130-BB73-471A-AED2-BAF14D2E753B Q36995072-93132750-36DE-41F8-8062-44512474BF71 Q37008871-06FF308C-DE5B-4A84-8293-5D686D11F8EC Q37278365-463FE872-7670-4899-A1BB-A18B3FB47FB9 Q37301269-9F2E0C44-85B8-42EB-B387-27E1EEC44D44 Q37330372-4124C903-029D-4384-8447-3BF07AA5FB80 Q37487765-2895C45F-15D7-4EBE-B936-F9CB519FCD40 Q37532566-38CFB2AE-5A57-4B5D-B8C1-2E8C84C0DE7E Q37716872-4220B441-1EC4-4187-A63C-D51B8EFB8024 Q37742014-8CE5DCA4-2454-4586-9532-638CED8B427D Q38088085-30A78983-339B-41E1-A948-16AB35806D6F Q38692839-8F236475-4B43-4766-B602-AD38E4C63BE4

P2860

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

http://www.wikidata.org/entity/Q33370331

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@ast

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@en

type

label

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@ast

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@en

prefLabel

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@ast

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@en

P1433

Q33370331-E26BDE94-2D61-4014-94FE-9262E876BAEE

P1476

Q33370331-BFE4C86B-7C33-4B12-A8DD-08B2B1D4F223

P2093

Q33370331-2B83B5F3-4873-4D87-AAF6-3FDD5FB3F1E7

Q33370331-50B09EDA-0902-497C-8452-323DD7AA5286

Q33370331-51B93BBE-7327-4EDC-8B99-3897F0C20839

Q33370331-556AFA9A-9331-4959-84EF-46AB7A637A2A

Q33370331-7B087DC4-A4B8-40AA-940D-53DEB94B302B

Q33370331-8E291C62-75DB-4AA4-9B28-C420360C6BE2

Q33370331-912907DE-E51F-4728-AB88-FA2831191ACD

Q33370331-91886924-8295-4EE2-9A3B-700117940665

Q33370331-976C5676-7649-4DAE-956A-ADD6D6153A4E

Q33370331-B8DFFF5E-4BF3-4A16-863B-F371A6CBBC3D

P304

Q33370331-D40A860F-7C39-4C73-9F33-019913562AA9

P31

Q33370331-A7DA1627-21EB-4001-8789-DEF365523FBF

P356

Q33370331-F6AF53FF-9C44-4B5B-BED0-931772765FE7

P433

Q33370331-76FF5913-02F1-4FE4-BEEF-B7345B79D1CD

P478

Q33370331-62A5D7BF-2405-4C10-BA10-E12EB3980D40

P50

Q33370331-1FAA7919-2EBC-425C-81F4-B6EC8EEDC961

Q33370331-5F6FEE4A-AF22-4B92-9063-350E97EB0F4B

Q33370331-72A7CAFE-45FB-452F-8363-A117C187745C

Q33370331-7B4E6803-31A8-41D5-B704-3A27F95F426A

Q33370331-F70D5D54-B1B0-4F61-A4D9-1C45D4142E9A

P577

Q33370331-D6957804-600A-4CC6-ACE0-D4F87889DFFC

P5875

Q33370331-5505682F-71FA-407B-8272-0525D7419A4B

P698

Q33370331-0073AD83-42BF-4BE7-95C0-61A458848176

P356

P1433

International Journal of Cancer

P1476

Docetaxel and gemcitabine comb ...... mas: a retrospective analysis.

@en

P2093

Angela Cioffi

http://www.w3.org/2001/XMLSchema#string

Christine Chevreau

http://www.w3.org/2001/XMLSchema#string

Etienne Brain

http://www.w3.org/2001/XMLSchema#string

Fabrice Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Frédéric Peyrade

http://www.w3.org/2001/XMLSchema#string

Georges Emile

http://www.w3.org/2001/XMLSchema#string

Groupe Sarcome Français

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Coindre

http://www.w3.org/2001/XMLSchema#string

Jérôme Fayette

http://www.w3.org/2001/XMLSchema#string

Nguyon Binh Bui

http://www.w3.org/2001/XMLSchema#string

P304

706-711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.21867

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Isabelle Ray-Coquard

Sophie Piperno-Neumann

Jacques-Olivier Bay

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7281776

http://www.w3.org/2001/XMLSchema#string

P698

16496406

http://www.w3.org/2001/XMLSchema#string